MICHAEL M. ANELLO, District Judge.
On December 7, 2018, Plaintiff Regina Marie Wagner ("Plaintiff") filed a Second Amended Complaint against Defendants Abbott Laboratories and Abbott Laboratories, Inc., d/b/a Abbott Sales, Marketing & Distribution Co. ("Defendants"), alleging two causes of action for strict products liability and negligence. See Doc. No. 17 (hereinafter "SAC").
Plaintiff Regina Marie Wagner resides in San Diego, California. SAC ¶ 1. Defendant Abbott Laboratories is an Illinois corporation, with its principal place of business in Illinois. See Doc. No. 24-1 at 1. Defendant Abbott Laboratories, Inc., d/b/a Abbott Sales, Marketing & Distribution Co. is a Delaware corporation, with its principal place of business in Illinois. See id. Defendant Abbott Laboratories Inc. is a wholly-owned subsidiary of Defendant Abbott Laboratories. See Doc. No. 23 at 2.
Plaintiff claims that on or about May 18, 2016, she learned from her treating physician that a medical device known as the Angio-Seal VIP Vascular Closure Device ("Angio-Seal Device")
Plaintiff alleges Defendants "owned, controlled, sold, assembled, manufactured and/or distributed the Angio-Seal Device[.]" Id. ¶ 9. Plaintiff contends her injury is attributable to "a defect in the manufacturing or assembly process" of the Angio-Seal Device and/or Defendants' "failure to provide adequate warnings of the danger(s) of said device." Id. ¶ 13. Plaintiff claims that prior to the implantation of the Angio-Seal Device in her right leg, she was "not provided with any warnings of any kind" related to the dangers associated with the Angio-Seal Device." Id. ¶ 10. Based on these allegations, Plaintiff commenced the instant action.
Under Federal Rule of Civil Procedure 12(b)(2), a defendant may move for dismissal based on lack of personal jurisdiction. On a motion to dismiss for lack of personal jurisdiction, "the plaintiff bears the burden of establishing that jurisdiction exists." Rio Props., Inc. v. Rio Int'l Interlink, 284 F.3d 1007, 1019 (9th Cir. 2002). Uncontroverted allegations in a complaint must be taken as true when a prima facie showing of personal jurisdiction is required. See Am. Tel. & Tel. Co. v. Compagnie Bruxelles Lambert, 94 F.3d 586, 588 (9th Cir. 1996). However, the court "may not assume the truth of allegations in a pleading which are contradicted by affidavit." Data Disc, Inc. v. Systems Tech. Assocs. Inc., 557 F.2d 1280, 1284 (9th Cir. 1977). Conflicts between facts contained in the parties' affidavits must be resolved in favor of the party asserting jurisdiction when deciding whether there has been a prima facie showing of personal jurisdiction. See Am. Tel. & Tel., 94 F.3d at 588.
The Court applies the personal jurisdiction law of the forum state where, as here, "there is no applicable federal statute governing personal jurisdiction[.]" Dole Food Co., Inc. v. Watts, 303 F.3d 1104, 1110 (9th Cir. 2002); see also Cal. Civ. Proc. Code § 410.10. "California's long-arm jurisdictional statute is coextensive with federal due process requirements[.]" Dole Food Co., 303 F.3d at 1110. A court may exercise personal jurisdiction "over a non-resident defendant" without offending constitutional principles if that defendant has "at least `minimum contacts' with the relevant forum such that the exercise of jurisdiction `does not offend traditional notions of fair play and substantial justice.'" Id. at 1110-11 (quoting Int'l Shoe Co. v. Washington, 326 U.S. 310, 316 (1945)).
A Rule 12(b)(6) motion to dismiss tests the sufficiency of the complaint. See Navarro v. Block, 250 F.3d 729, 732 (9th Cir. 2001). A pleading must contain "a short and plain statement of the claim showing that the pleader is entitled to relief." Fed. R. Civ. P. 8(a)(2). However, plaintiffs must also plead "enough facts to state a claim to relief that is plausible on its face." Fed. R. Civ. P. 12(b)(6); Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). The plausibility standard thus demands more than a formulaic recitation of the elements of a cause of action, or naked assertions devoid of further factual enhancement. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). Instead, the complaint "must contain sufficient allegations of underlying facts to give fair notice and to enable the opposing party to defend itself effectively." Starr v. Baca, 652 F.3d 1202, 1216 (9th Cir. 2011).
In reviewing a motion to dismiss under Rule 12(b)(6), courts must assume the truth of all factual allegations and must construe them in the light most favorable to the nonmoving party. Cahill v. Liberty Mut. Ins. Co., 80 F.3d 336, 337-38 (9th Cir. 1996). The court need not take legal conclusions as true merely because they are cast in the form of factual allegations. Roberts v. Corrothers, 812 F.2d 1173, 1177 (9th Cir. 1987). Similarly, "conclusory allegations of law and unwarranted inferences are not sufficient to defeat a motion to dismiss." Pareto v. FDIC, 139 F.3d 696, 699 (9th Cir. 1998).
In determining the propriety of a Rule 12(b)(6) dismissal, courts generally may not look beyond the complaint for additional facts. United States v. Ritchie, 342 F.3d 903, 908 (9th Cir. 2003). "A court may, however, consider certain materials—documents attached to the complaint, documents incorporated by reference in the complaint, or matters of judicial notice—without converting the motion to dismiss into a motion for summary judgment." Id.; see also Lee v. City of L.A., 250 F.3d 668, 688 (9th Cir. 2001). "However, [courts] are not required to accept as true conclusory allegations which are contradicted by documents referred to in the complaint." Steckman v. Hart Brewing, Inc., 143 F.3d 1293, 1295-96 (9th Cir. 1998). Where dismissal is appropriate, a court should grant leave to amend unless the plaintiff could not possibly cure the defects in the pleading. Knappenberger v. City of Phoenix, 566 F.3d 936, 942 (9th Cir. 2009).
As an initial matter, Defendants request the Court take judicial notice of the following four documents in support of its motion: (1) Exhibit 1: the FDA's 1996 premarket approval of the first Angio-Seal product; (2) Exhibit 2: the FDA's 2018 approval of a supplement to the Angio-Seal VIP product; (3) Exhibit 3: the Form 8-K for St. Jude Medical, LLC dated January 4, 2017; and (4) Exhibit 4: a news article entitled "Terumo Completes Acquisition of Certain Abbott and St. Jude Medical Assets," dated January 24, 2017. See Doc. No. 24-4 at 1. Plaintiff did not file an opposition to Defendants' request for judicial notice.
Generally, a district court's review on a motion to dismiss is "limited to the complaint." Lee, 250 F.3d at 688 (quoting Cervantes v. City of San Diego, 5 F.3d 1273, 1274 (9th Cir. 1993)). However, "a court may take judicial notice of matters of public record." Id. at 689 (internal quotations omitted). Additionally, the Ninth Circuit has indicated that in granting a request for judicial notice, courts must "clearly specify what fact or facts it judicially noticed[.]" Khoja v. Orexigen Therapeutics Inc., 899 F.3d 988, 999 (9th Cir. 2018).
With respect to Exhibits 1, 2, and 4, the Court need not rely on these documents in reaching its conclusion below. As such, the Court
In the SAC, Plaintiff generally asserts the Court has personal jurisdiction over Defendants, but does not specify between general or specific personal jurisdiction.
"[I]f a defendant has not had continuous and systematic contacts with the state sufficient to confer `general jurisdiction,'" Dole Food Co., 303 F.3d at 1111, specific personal jurisdiction may be established by showing the following:
Picot v. Weston, 780 F.3d 1206, 1211 (9th Cir. 2015) (citing Schwarzenegger v. Fred Martin Motor Co., 374 F.3d 797, 802 (9th Cir. 2004)). Plaintiff bears the burden of satisfying the first two prongs of the test for specific jurisdiction. Dole Food Co., 303 F.3d at 1108 (citing Sher v. Johnson, 911 F.2d 1357, 1361 (9th Cir. 1990)).
The Ninth Circuit has emphasized that under the first prong of the specific personal jurisdiction test, purposeful availment and purposeful direction are two separate and distinct concepts. Specifically, "[t]he exact form of our jurisdictional inquiry depends on the nature of the claim at issue." Picot, 780 F.3d at 1212. For claims sounding in contract, courts generally apply the "purposeful availment" analysis, which considers whether a defendant has purposefully availed himself of the privilege of conducting business with the forum state. Id. (citing Schwarzenegger, 374 F.3d at 802). For claims sounding in tort, courts apply a "purposeful direction" test, and analyze whether the defendant "has directed his actions at the forum state, even if those actions took place elsewhere." Id. (citing Schwarzenegger, 374 F.3d at 802-03). Because Plaintiff's SAC sounds in tort, the latter test is applicable.
Here, Plaintiff asserts that Defendants "purposefully directed" their activities at California through marketing and sales efforts related to the Angio-Seal Device, and because the Angio-Seal Device was "deployed in plaintiff's leg in California." Doc. No. 25 at 5. Even assuming Plaintiff's allegations are sufficient to satisfy the first prong of the specific jurisdiction test, Plaintiff has not met her burden with respect to the second prong of the test. The second prong requires Plaintiff's claim to be one which "arises out of or relates to the defendant's forum-related activities." Picot, 780 F.3d at 1211 (emphasis added). The Ninth Circuit has "referred to the second prong of the specific jurisdiction test as a `but for' test." In re W. States Wholesale Natural Gas Antitrust Litig., 715 F.3d 716, 742 (9th Cir. 2013) (quoting Shute v. Carnival Cruise Lines, 897 F.2d 377, 385 (9th Cir. 1990), rev'd on other grounds, Carnival Cruise Lines, Inc. v. Shute, 499 U.S. 585 (1991)). "Under the `but for' test, `a lawsuit arises out of a defendant's contacts with the forum state if a direct nexus exists between those contacts and the cause of action.'" Id. (quoting Fireman's Fund Ins. Co. v. Nat'l Bank of Coops., 103 F.3d 888, 894 (9th Cir. 1996)); see also Harlow v. Children's Hosp., 432 F.3d 50, 61 (1st Cir. 2005) (noting that when analyzing specific personal jurisdiction, "contacts must generally be limited to those before and surrounding the accrual of the cause of action.").
Plaintiff summarily states that Defendants "owned, controlled, sold, assembled, manufactured and/or distributed the Angio-Seal Device" at the time of Plaintiff's injury. SAC ¶ 9. However, Defendants Abbott Laboratories and Abbott Laboratories, Inc. never "owned, manufactured, or sold the Angio-Seal line products." Doc. No. 24-1 at 7. On January 4, 2017—nearly eight months after Plaintiff discovered the failed Angio-Seal device in her leg—Defendant Abbott Laboratories acquired St. Jude Medical, Inc.
Additionally, the Court noted in its prior order that the parties did not address whether successor liability could serve as the basis for specific personal jurisdiction in this case. See Doc. No. 16 at 12 n.10. Courts "will have personal jurisdiction over a successor company if (1) the court would have had personal jurisdiction over the predecessor[;] and (2) the successor company effectively assumed the subject liabilities of the predecessor." Lefkowtiz v. Scytl USA, No. 15-cv-05005-JSC, 2016 WL 537952, at *3 (N.D. Cal. Feb. 11, 2016) (quoting CenterPoint Energy, Inc. v. Superior Court, 69 Cal.Rptr.3d 202, (Ct. App. 2007)); see also Successor Agency to Former Emeryville Redevelopment Agency and City of Emeryville v. Swagelock Co., No. 17-cv-308-WHO, 2019 WL 377747, at *6 (N.D. Cal. Jan. 30, 2019) (utilizing theory of successor liability to determine whether the plaintiff's claim arises out of or relates to the defendant's contacts with the forum).
Defendants argue that "Abbott Laboratories' purchase of the previous owner of the Angio-Seal products" cannot serve as the basis for jurisdiction, because it "did not assume the liabilities associated with the Angio-Seal products[.]" Doc. No. 24-1 at 9. Defendants maintain that St. Jude Medical, LLC is the successor to St. Jude Medical, Inc. See id. at 8; see also RJN at 11. Plaintiff does not allege that Defendant Abbott Laboratories assumed the liabilities associated with the Angio-Seal products, nor does Plaintiff respond to Defendants' argument regarding successor liability. As such, Plaintiff fails establish that her claims arise out of or relate to Defendants' contacts with the forum based on a theory of successor liability. See Dole Food Co., 303 F.3d at 1108.
In sum, the Court finds that Plaintiff has not met her burden of establishing that the Court has personal jurisdiction over Defendants. Even if Plaintiff could satisfy the first prong of the specific personal jurisdiction test, Plaintiff fails to show that her claims arise out of or relate to Defendants' forum-related activities. See Picot, 780 F.3d at 1211. Accordingly, the Court concludes that it lacks personal jurisdiction over Defendants, and
Based on the foregoing, the Court